📊 CELZ Key Takeaways
Is Creative Medical Technology Holdings, Inc.. (CELZ) a Good Investment?
Creative Medical Technology Holdings has deteriorated to zero revenue with -45.5% YoY decline, indicating complete operational collapse or stalled business model. The company is burning $1.3M in cash per period against only $5.7M in reserves, providing minimal 4-5 quarter runway. Without immediate revenue generation or path to profitability, severe financial distress is imminent.
Creative Medical Technology Holdings shows essentially no operating scale, with just $6K of revenue against more than $6M of operating losses and negative operating cash flow of $5.86M. While the balance sheet appears liquid due to $7.21M of cash and low reported liabilities, the business currently lacks revenue traction and is consuming cash at a pace that raises major concerns about sustainability and growth quality.
Creative Medical Technology Holdings, Inc.. Key Strengths (CELZ)
- Strong liquidity position with 19.69x current ratio provides immediate debt servicing capability
- Cash reserves of $5.7M provide short-term financial cushion and operational flexibility
- Manageable debt-to-equity ratio of 0.84x limits financial leverage and bankruptcy risk
- Large cash balance relative to reported near-term obligations supports short-term liquidity
- Very high current and quick ratios indicate no immediate working-capital stress
- Low absolute liabilities versus assets suggests some balance-sheet flexibility if data is accurate
CELZ Stock Risks: Creative Medical Technology Holdings, Inc.. Investment Risks
- Zero revenue with 45.5% YoY decline indicates complete loss of business operations or early-stage pre-revenue failure
- Negative operating cash flow of -$1.3M rapidly depletes remaining cash reserves within 4-5 quarters
- Persistent operating losses (-$1.5M) and net losses (-$1.4M) with no visible path to profitability
- Revenue base is negligible and declined 45.5% year over year, indicating weak commercial execution
- Operating and free cash flow losses are severe, implying continued dependence on external financing or capital depletion
- Reported balance-sheet figures appear internally inconsistent because long-term debt exceeds total liabilities, increasing uncertainty around data quality and true leverage
Key Metrics to Watch
- Quarterly revenue generation and trajectory toward positive sales
- Monthly cash burn rate and months of remaining operational runway
- Operating cash flow stabilization and movement toward cash flow breakeven
- Quarterly revenue growth and evidence of commercial scale-up
- Cash burn relative to cash balance, including operating cash flow and financing needs
Creative Medical Technology Holdings, Inc.. (CELZ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 19.69x current ratio provides a solid financial cushion.
CELZ Profit Margin, ROE & Profitability Analysis
CELZ vs Healthcare Sector: How Creative Medical Technology Holdings, Inc.. Compares
How Creative Medical Technology Holdings, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Creative Medical Technology Holdings, Inc.. Stock Overvalued? CELZ Valuation Analysis 2026
Based on fundamental analysis, Creative Medical Technology Holdings, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Creative Medical Technology Holdings, Inc.. Balance Sheet: CELZ Debt, Cash & Liquidity
CELZ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Creative Medical Technology Holdings, Inc..'s revenue has declined by 93% over the 5-year period, indicating business contraction. The most recent EPS of $-3.71 indicates the company is currently unprofitable.
CELZ Revenue Growth, EPS Growth & YoY Performance
CELZ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$1.4M | $-0.38 |
| Q3 2025 | N/A | -$1.0M | $-0.48 |
| Q2 2025 | N/A | -$1.2M | $-0.48 |
| Q1 2025 | N/A | -$1.0M | $0.73 |
| Q3 2024 | N/A | -$1.0M | N/A |
| Q2 2024 | N/A | -$1.1M | N/A |
| Q1 2024 | N/A | -$1.0M | N/A |
| Q3 2023 | $6.0K | -$982.3K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Creative Medical Technology Holdings, Inc.. Dividends, Buybacks & Capital Allocation
CELZ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Creative Medical Technology Holdings, Inc.. (CIK: 0001187953)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CELZ
What is the AI rating for CELZ?
Creative Medical Technology Holdings, Inc.. (CELZ) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CELZ's key strengths?
Claude: Strong liquidity position with 19.69x current ratio provides immediate debt servicing capability. Cash reserves of $5.7M provide short-term financial cushion and operational flexibility. ChatGPT: Large cash balance relative to reported near-term obligations supports short-term liquidity. Very high current and quick ratios indicate no immediate working-capital stress.
What are the risks of investing in CELZ?
Claude: Zero revenue with 45.5% YoY decline indicates complete loss of business operations or early-stage pre-revenue failure. Negative operating cash flow of -$1.3M rapidly depletes remaining cash reserves within 4-5 quarters. ChatGPT: Revenue base is negligible and declined 45.5% year over year, indicating weak commercial execution. Operating and free cash flow losses are severe, implying continued dependence on external financing or capital depletion.
What is CELZ's revenue and growth?
Creative Medical Technology Holdings, Inc.. reported revenue of $0.0.
Does CELZ pay dividends?
Creative Medical Technology Holdings, Inc.. does not currently pay dividends.
Where can I find CELZ SEC filings?
Official SEC filings for Creative Medical Technology Holdings, Inc.. (CIK: 0001187953) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CELZ's EPS?
Creative Medical Technology Holdings, Inc.. has a diluted EPS of $-0.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CELZ's fundamental grade?
Based on our AI fundamental analysis in June 2026, Creative Medical Technology Holdings, Inc.. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CELZ stock overvalued or undervalued?
Valuation metrics for CELZ: ROE of -23.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CELZ's AI grade for 2026?
Our dual AI analysis gives Creative Medical Technology Holdings, Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CELZ's free cash flow?
Creative Medical Technology Holdings, Inc..'s operating cash flow is $-1.3M, with capital expenditures of N/A.
How does CELZ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -23.0% (avg: 15%), current ratio 19.69 (avg: 2).